Active ingredients
Pharmacological Group
Used in the treatment
- S06 Intracranial injury
- R47 Speech disturbances, not elsewhere classified
- R41.8.0* Intellectual and mnestic disorders
- R41.3.0* Memory reduction
- N95.1 Menopausal and female climacteric states
- I70 Atherosclerosis
- I69 Sequelae of cerebrovascular disease
- I67.9 Cerebrovascular disease, unspecified
- I47.1 Supraventricular tachycardia
- I15 Secondary hypertension
- I10 Essential (primary) hypertension
- H91 Other hearing loss
- H83.9 Disease of inner ear, unspecified
- H83.2 Labyrinthine dysfunction
- H81.9 Disorder of vestibular function, unspecified
- H36.0 Diabetic retinopathy (E10-E14+ with common fourth character .3)
- G93.2 Benign intracranial hypertension
- G43 Migraine
- F90.0 Disturbance of activity and attention
- F80-F89 Disorders of psychological development